CFFP
CRSP icon

Center for Financial Planning’s CRISPR Therapeutics CRSP Stock Holding History

Center for Financial Planning’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$546 Hold
10
– – ﹤0.01% 624
2026
Q1 		$476 Hold
10
– – ﹤0.01% 618
2025
Q4 		$525 Hold
10
– – ﹤0.01% 651
2025
Q3 		$649 Hold
10
– – ﹤0.01% 625
2025
Q2 		$487 Hold
10
– – ﹤0.01% 613
2025
Q1 		$341 Hold
10
– – ﹤0.01% 674
2024
Q4 		$394 Hold
10
– – ﹤0.01% 639
2024
Q3 		$470 Hold
10
– – ﹤0.01% 539
2024
Q2 		$541 Hold
10
– – ﹤0.01% 548
2024
Q1 		$682 Hold
10
– – ﹤0.01% 569
2023
Q4 		$626 Hold
10
– – ﹤0.01% 496
2023
Q3 		$454 Hold
10
– – ﹤0.01% 498
2023
Q2 		$562 Hold
10
– – ﹤0.01% 538
2023
Q1 		$453 Hold
10
– – ﹤0.01% 504
2022
Q4 		$406 Hold
10
– – ﹤0.01% 514
2022
Q3 		$1K Hold
10
– – ﹤0.01% 586
2022
Q2 		$1K Hold
10
– – ﹤0.01% 493
2022
Q1 		$1K Hold
10
– – ﹤0.01% 494
2021
Q4 		$1K Hold
10
– – ﹤0.01% 503
2021
Q3 		$1K Hold
10
– – ﹤0.01% 468
2021
Q2 		$2K Hold
10
– – ﹤0.01% 455
2021
Q1 		$1K Buy
+10
New +$1.51K ﹤0.01% 504

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Center for Financial Planning's CRSP Position: Q2 2026 in Review

Center for Financial Planning held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 10 shares worth $546. The position accounts for ﹤0.01% of the portfolio, ranked #624.

Center for Financial Planning first reported a position in CRSP in Q1 2021 and has held it in 22 quarters since. The position peaked at $2K in Q2 2021. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Center for Financial Planning held 10 shares of CRISPR Therapeutics worth $546 as of Q2 2026.
  • Center for Financial Planning left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Center for Financial Planning's portfolio in Q2 2026, its #624 holding.
  • Center for Financial Planning first reported a position in CRISPR Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • Center for Financial Planning's CRISPR Therapeutics position peaked at $2K in Q2 2021.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Center for Financial Planning's 13F filing for Q2 2026, filed 21 Jul 2026.